SPECIAL SEMINAR I Different perspectives : Analysis of France’s decision not to reimburse Alzheimer’s treatment
EventsThe Transparency Commission of the French National Authority for Health recently decided not to reimburse an Alzheimer’s drug (Lecanemab) that had been granted marketing authorisation in the European Union. What scientific, clinical and medico-economic issues explain or challenge this decision? To discuss we will have presentations from experts from various backgrounds: – Driss Berdaï […]